Due to a large untreated patient pool and the recent
approval of new treatments, the hepatitis C market will more than treble from
$5.7 billion in 2012 to $18.6 billion by 2019, at an impressive Compound Annual
Growth Rate (CAGR) of 18.5%.
The company’s new report* states that the hepatitis C
market will receive this major boost with the 2013 approval of Sovaldi, which
has the potential to transform the treatment algorithm for hepatitis C. Due to
the clinical potential of the drug, Sovaldi will be very expensive, reaching a
cost of $86,000 annually and setting a high price benchmark for future drugs.
Inquire about this report: http://www.marketresearchreports.com/gbi-research/hepatitis-c-therapeutics-major-developed-markets-2019-outstanding-recent-approvals-and
Analyst of this report says: “Sovaldi boasts excellent
tolerability and a Sustained Virologic Response rate approaching 100%, without
specificity to any genotype 1. In genotypes 2 and 3, Sovaldi is administered
with ribavirin alone, alleviating the need for Pegasys or Pegintron and
therefore reducing the rate of adverse events associated with these two
therapies. As a result, many patients who have previously deferred treatment
are expected to re-enter the market and use Sovaldi.”
Additional drugs, such as Olysio, which was also approved
in 2013, and daclatasvir are anticipated to compete with Sovaldi, although they
are not proven to be as effective and can only be used in genotype 1 infections.
According to publisher, Sovaldi-ledipasvir and ABT-450
triple therapy will further advance the hepatitis C market and displace older
drugs from 2015 onwards. This is due to the fact that these therapies can be
used without peginterferon and have demonstrated 100% efficacy in genotype 1,
with strong tolerability and low dosing.
“The late-stage pipeline for hepatitis C is exceptionally
promising, and we expect new products to completely transform the clinical and
commercial landscape during the forecast period,” Analyst concludes.
This report provides in-depth analysis of the major
antiviral drugs used in the treatment of hepatitis C, including analyses of
their safety, efficacy, treatment patterns and strengths/weaknesses. It also
gives a market forecast between 2012 and 2019.
Find Other Reports at our Diseases Section: http://www.marketresearchreports.com/diseases
For regular industry updates subscribe to our newsletter
at: http://www.marketresearchreports.com/subscribe-to-newsletter
No comments:
Post a Comment
Note: only a member of this blog may post a comment.